@article{fdi:010077424,
  title = {{I}ncreasing levels of pretreatment {HIV} drug resistance and safety concerns for dolutegravir use in women of reproductive age},
  author = {{I}nzaule, {S}. {C}. and {J}ordan, {M}. {R}. and {C}ournil, {A}mandine and {V}itoria, {M}. and {R}avasi, {G}. and {C}ham, {F}. and {L}e, {L}. {V}. and {D}zangare, {J}. and {H}amunime, {N}. and {M}utenda, {N}. and {A}ghokeng {F}obang, {A}velin and {B}issek, {A}. and {B}illong, {S}. and {K}aleebu, {P}. and {D}oherty, {M}. and {B}ertagnolio, {S}.},
  editor = {},
  language = {{ENG}},
  abstract = {{U}se of dolutegravir-based first-line antiretroviral therapy ({ART}) in response to rising levels of pretreatment {HIV} drug resistance ({PDR}) to non-nucleoside reverse transcriptase inhibitors ({NNRTI}s) may be limited, given safety concerns for birth defects in women of child-bearing potential. {P}ooled data from 11 nationally representative surveys show that {NNRTI} {PDR} in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-{NNRTI}-based {ART} regimen in this population.},
  keywords = {{AFRIQUE} {SUBSAHARIENNE} ; {AMERIQUE} {LATINE} ; {ASIE} {DU} {SUD} {EST}},
  booktitle = {},
  journal = {{AIDS}},
  volume = {33},
  numero = {11},
  pages = {1797--1799},
  ISSN = {0269-9370},
  year = {2019},
  DOI = {10.1097/qad.0000000000002277},
  URL = {https://www.documentation.ird.fr/hor/fdi:010077424},
}